FluBlok, a next generation influenza vaccine manufactured in insect cells
FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe...
Saved in:
| Published in | Biologicals Vol. 37; no. 3; pp. 182 - 189 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.06.2009
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects.
The insect cell–baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus–insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for
expresSF cell line used for the manufacturing of FluBlok.
In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses. |
|---|---|
| AbstractList | FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell-baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus-insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses. FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell-baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus-insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses.FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell-baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus-insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses. FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing process presents the possibility for safe and expeditious vaccine production. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. The high purity of the antigen enables administration at higher doses without a significant increase in side-effects in human subjects. The insect cell–baculovirus production technology is particularly suitable for influenza where annual adjustment of the vaccine is required. The baculovirus–insect expression system is generally considered a safe production system, with limited growth potential for adventitious agents. Still regulators question and challenge the safety of this novel cell substrate as FluBlok continues to advance toward product approval. This review provides an overview of cell substrate characterization for expresSF cell line used for the manufacturing of FluBlok. In addition, this review includes an update on the clinical development of FluBlok. The highly purified protein vaccine, administered at three times higher antigen content than TIV, is well tolerated and results in stronger immunogenicity, a long lasting immune response and provides cross-protection against drift influenza viruses. |
| Author | Hollister, Jason R. Cox, Manon M.J. |
| Author_xml | – sequence: 1 givenname: Manon M.J. surname: Cox fullname: Cox, Manon M.J. email: manon.cox@proteinsciences.com – sequence: 2 givenname: Jason R. surname: Hollister fullname: Hollister, Jason R. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19297194$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU9P3DAQxS1Exb_yFar0womkY2_s2KeKroAiIfXSni2vM155ydpgJ4jy6fGyS1X1UmRLHsm_eTN675jshxiQkM8UGgpUfFk1Cx-HuPTWDLlhAKoB1gBt98gRBcVrOWOwv6lbXlPg4pAc57wCoLTt2gNySBVTHVXtEbm5GqZvQ7w7r0wV8GmslhgwmdHHUPnghgnDs6kejbU-YLU2YXLGjlPCvnyXm9GOlcVhyB_JB1fWwdPde0J-XV3-nH-vb39c38wvbmvbdmysLe1ka3shBUfTL2a8V0KaVlImHRdMclwo0yuLblaO4cqyzlEupXMCKIjZCTnb6t6n-DBhHvXa580GJmCcshYd6wRj6r8ggzIOOCvgpx04LdbY6_vk1yb91m8uFeDrFrAp5pzQaevHV4_GZPygKehNLnql_8pFb3LRwHTJpSiofxT-DHlH73zbi8XVR49JZ-sxWOx9Ku7rPvp3qLwAf1CvRg |
| CitedBy_id | crossref_primary_10_1002_elsc_200900040 crossref_primary_10_1016_j_vaccine_2014_02_015 crossref_primary_10_1016_j_vaccine_2018_01_050 crossref_primary_10_1038_s41598_019_56169_5 crossref_primary_10_3390_biom11081072 crossref_primary_10_1007_s12250_012_3241_1 crossref_primary_10_1016_j_vaccine_2014_03_058 crossref_primary_10_1016_j_vaccine_2017_03_102 crossref_primary_10_1186_1472_6750_13_50 crossref_primary_10_1038_s41541_020_00227_x crossref_primary_10_1017_S1466252312000175 crossref_primary_10_1016_j_tibtech_2011_04_007 crossref_primary_10_1128_genomeA_00829_17 crossref_primary_10_1002_jctb_2574 crossref_primary_10_1186_1743_422X_8_353 crossref_primary_10_1111_j_1365_2761_2012_01348_x crossref_primary_10_3390_vaccines10081256 crossref_primary_10_1016_j_aspen_2017_03_021 crossref_primary_10_1007_BF03256169 crossref_primary_10_1038_s41591_018_0340_z crossref_primary_10_1016_j_vaccine_2012_04_095 crossref_primary_10_3390_vaccines12111220 crossref_primary_10_1016_j_vaccine_2020_07_023 crossref_primary_10_1002_bit_23028 crossref_primary_10_1016_j_jip_2011_05_010 crossref_primary_10_1128_CVI_00290_09 crossref_primary_10_1080_14760584_2022_2085565 crossref_primary_10_1139_cjz_2012_0258 crossref_primary_10_1128_mBio_01996_15 crossref_primary_10_1038_s41392_023_01724_w crossref_primary_10_1111_febs_17331 crossref_primary_10_3390_vaccines3010022 crossref_primary_10_1142_S1568558609000126 crossref_primary_10_1016_j_coche_2013_09_002 crossref_primary_10_1371_journal_pone_0032741 crossref_primary_10_3389_fimmu_2023_1147028 crossref_primary_10_1016_j_biologicals_2012_12_001 crossref_primary_10_1002_biot_202200466 crossref_primary_10_1002_biot_201400387 crossref_primary_10_1016_j_virol_2024_110038 crossref_primary_10_1111_febs_15787 crossref_primary_10_4161_hv_19106 crossref_primary_10_1007_s12275_017_7306_6 crossref_primary_10_1016_j_jip_2011_05_003 crossref_primary_10_1016_j_omtm_2020_09_018 crossref_primary_10_15653_TPG_150413 crossref_primary_10_1038_s41598_025_86921_z crossref_primary_10_1007_s00108_021_01101_1 crossref_primary_10_1016_j_vaccine_2021_11_054 crossref_primary_10_1016_j_jip_2011_05_009 crossref_primary_10_1016_S1576_9887_12_70039_0 crossref_primary_10_1128_JVI_00780_14 crossref_primary_10_1080_14760584_2021_1984887 crossref_primary_10_1016_j_vaccine_2025_126707 crossref_primary_10_2217_fvl_12_122 crossref_primary_10_1016_j_addr_2014_10_023 crossref_primary_10_3390_vaccines11040780 crossref_primary_10_1002_bit_24493 crossref_primary_10_1586_erv_09_128 crossref_primary_10_1016_S0325_7541_13_70028_2 crossref_primary_10_1016_j_virusres_2011_09_024 crossref_primary_10_1016_j_arr_2010_09_005 crossref_primary_10_1016_j_vaccine_2021_04_033 crossref_primary_10_1586_erv_11_24 crossref_primary_10_1186_s12896_015_0152_x crossref_primary_10_1002_elsc_201300131 crossref_primary_10_1080_21645515_2021_1875761 crossref_primary_10_3390_vaccines11071218 crossref_primary_10_1016_j_imu_2021_100809 crossref_primary_10_1371_journal_pone_0137822 crossref_primary_10_1016_j_vaccine_2020_10_073 crossref_primary_10_1371_journal_pone_0060835 crossref_primary_10_1021_acsami_4c16246 crossref_primary_10_1038_s41541_021_00292_w crossref_primary_10_1016_j_vaccine_2012_10_054 crossref_primary_10_1002_bit_24542 crossref_primary_10_1002_cpz1_55 crossref_primary_10_1002_bit_25634 crossref_primary_10_3390_vaccines9091032 crossref_primary_10_1016_j_nano_2018_08_010 crossref_primary_10_1016_j_vaccine_2011_01_081 crossref_primary_10_1038_s41467_025_56496_4 crossref_primary_10_1128_JVI_00541_14 crossref_primary_10_1586_erv_12_24 crossref_primary_10_1371_journal_pntd_0002124 crossref_primary_10_1016_j_jsb_2018_03_004 crossref_primary_10_1038_s42003_024_06516_8 crossref_primary_10_1016_j_jbiosc_2010_06_001 crossref_primary_10_1016_j_vaccine_2009_10_048 crossref_primary_10_1017_S146625231000006X crossref_primary_10_1007_s12010_016_2064_1 crossref_primary_10_1186_s43141_023_00581_y crossref_primary_10_1080_21645515_2015_1016675 crossref_primary_10_1016_j_vaccine_2018_09_034 crossref_primary_10_3390_vaccines12060667 crossref_primary_10_1016_j_aspen_2019_10_002 crossref_primary_10_1016_j_jbiotec_2018_02_001 crossref_primary_10_1016_j_vaccine_2024_03_034 crossref_primary_10_1016_j_jbiotec_2016_06_029 crossref_primary_10_3390_vaccines10101655 crossref_primary_10_1371_journal_pone_0025816 crossref_primary_10_1016_j_vaccine_2017_02_043 crossref_primary_10_1021_acs_iecr_8b00985 crossref_primary_10_1016_j_jsb_2010_02_010 crossref_primary_10_1111_j_1439_0418_2010_01574_x crossref_primary_10_1002_mas_21629 crossref_primary_10_1586_erv_11_82 crossref_primary_10_3390_cells10061412 crossref_primary_10_1016_j_vaccine_2018_09_021 crossref_primary_10_1186_s12896_017_0412_z crossref_primary_10_3390_biomedicines12010028 crossref_primary_10_1080_21645515_2015_1094595 crossref_primary_10_1371_journal_pone_0061790 crossref_primary_10_1016_j_stem_2025_01_014 crossref_primary_10_3390_ijms252211979 crossref_primary_10_1016_j_cell_2023_04_024 crossref_primary_10_1016_j_virol_2017_09_025 crossref_primary_10_1016_j_vaccine_2023_08_009 crossref_primary_10_3390_vaccines9020171 crossref_primary_10_1002_cite_201200153 crossref_primary_10_1146_annurev_virology_010320_044746 crossref_primary_10_3390_v17020136 crossref_primary_10_1016_j_vaccine_2019_01_068 crossref_primary_10_3389_fchem_2022_863118 crossref_primary_10_3390_vaccines9090979 crossref_primary_10_1155_2015_504831 crossref_primary_10_1002_bit_25142 crossref_primary_10_1080_21645515_2016_1187343 crossref_primary_10_3389_fmicb_2020_00135 crossref_primary_10_1016_j_vaccine_2023_07_061 crossref_primary_10_1371_journal_pone_0187718 crossref_primary_10_1016_j_vaccine_2015_03_052 crossref_primary_10_1038_s41541_019_0153_1 crossref_primary_10_3389_fimmu_2020_01100 crossref_primary_10_1016_j_pep_2024_106641 crossref_primary_10_1128_JVI_01150_19 crossref_primary_10_1016_j_bbamem_2023_184239 crossref_primary_10_2217_fvl_15_75 crossref_primary_10_1007_s40265_013_0103_6 crossref_primary_10_1016_j_biotechadv_2011_09_014 |
| Cites_doi | 10.1186/1743-422X-2-20 10.1126/science.1188388 10.1159/000148895 10.1111/j.1750-2659.2006.00007.x 10.1016/0264-410X(94)90227-5 10.12665/J25.Holtz 10.1016/j.biologicals.2008.07.005 10.1016/j.biologicals.2007.11.005 10.1086/508493 10.1001/jama.297.14.1577 10.1128/JVI.00807-07 10.1128/CMR.18.4.608-637.2005 10.1016/j.biologicals.2008.08.001 10.1016/j.jbiotec.2005.05.009 10.1186/1471-2148-1-3 10.1016/S0168-1702(01)00280-5 10.1006/biol.1994.1030 10.1093/nar/26.7.1628 10.1016/0168-1702(86)90004-3 10.1111/j.1750-2659.2008.00053.x 10.1007/BF02615077 10.1128/CDLI.3.5.507-510.1996 10.1016/j.jviromet.2004.08.020 10.1128/JCM.32.10.2468-2473.1994 10.1016/j.vaccine.2005.11.005 10.1007/BF01311693 10.1086/503050 |
| ContentType | Journal Article |
| Copyright | 2009 The International Association for Biologicals |
| Copyright_xml | – notice: 2009 The International Association for Biologicals |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7SS 7T5 7U9 H94 7X8 |
| DOI | 10.1016/j.biologicals.2009.02.014 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Entomology Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Entomology Abstracts AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | Entomology Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1095-8320 |
| EndPage | 189 |
| ExternalDocumentID | 19297194 10_1016_j_biologicals_2009_02_014 S1045105609000281 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5VS 6J9 7-5 71M 8P~ 9JM AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR LG5 LUGTX LZ5 M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSU SSZ T5K UNMZH WUQ XPP ZMT ~G- ~KM AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EFKBS EIF NPM 7SS 7T5 7U9 H94 7X8 |
| ID | FETCH-LOGICAL-c472t-c1784cd6865eadb35d968a48128f56285eb9ad9cef3f3fa59c27f1588ff601063 |
| IEDL.DBID | AIKHN |
| ISSN | 1045-1056 1095-8320 |
| IngestDate | Fri Jul 11 10:15:59 EDT 2025 Fri Jul 11 08:39:15 EDT 2025 Mon Jul 21 06:01:11 EDT 2025 Tue Jul 01 03:56:45 EDT 2025 Thu Apr 24 22:59:02 EDT 2025 Fri Feb 23 02:34:22 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Cell substrate Baculovirus Hemagglutinin Influenza vaccine Insect cells |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c472t-c1784cd6865eadb35d968a48128f56285eb9ad9cef3f3fa59c27f1588ff601063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-3 |
| PMID | 19297194 |
| PQID | 20628052 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_67276229 proquest_miscellaneous_20628052 pubmed_primary_19297194 crossref_citationtrail_10_1016_j_biologicals_2009_02_014 crossref_primary_10_1016_j_biologicals_2009_02_014 elsevier_sciencedirect_doi_10_1016_j_biologicals_2009_02_014 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-06-01 |
| PublicationDateYYYYMMDD | 2009-06-01 |
| PublicationDate_xml | – month: 06 year: 2009 text: 2009-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Biologicals |
| PublicationTitleAlternate | Biologicals |
| PublicationYear | 2009 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | (bib34) 2007 Chen, Nims, Dusing, Miller, Luo, Quertinmont (bib15) 2008 Knezevic, Stacey, Petricciani (bib19) 2008; 36 Vaughn, Goodwin, Tompkins, McCawley (bib20) 1977; 13 Treanor, Schiff, Couch, Cate, Brady, Hay (bib2) 2006; 193 Li, Scotti, Miyamura, Takeda (bib33) 2007; 81 Huber, McCullers (bib8) 2008; 10 Cox, Anderson (bib1) 2007; 1 Keitel, Cate, Atmar, Turner, Nino, Dukes (bib4) 1996; 3 McPherson (bib21) 2008 Jarrett, Johnson, Wilson, Gallagher (bib29) 2006; 123 Wood (bib6) 1998 (bib16) 1998 Keitel, Couch, Cate, Hess, Baxter, Quarles (bib5) 1994; 32 Huhtala, Linko, Mutharasan (bib27) 2005; 118 (bib36) 2007 Rohwer (bib13) 1996; 88 Terzian, Pelisson, Bucheton (bib32) 2001; 1 Bridges, Fukuda, Uyeki, Cox, Singleton (bib7) 2002; 51 Renfrey, Watts (bib39) 1994; 12 Wang, Holtz, Anderson, Chubet, Mahmoud, Cox (bib10) 2006; 24 Rose, Schultz, Henikoff, Pietrokovski, McCallum, Henikoff (bib31) 1998; 26 Yoden, Kida, Kuwabara, Yanagawa, Webster (bib12) 1986; 4 Green, Baron (bib22) 1975; 190 Kida, Webster, Yanagawa (bib11) 1983; 76 Nims (bib14) 2006; 123 (bib35) 2007 Kuno, Chang (bib17) 2005; 18 Khan, Sears (bib25) 2001; 106 Rose (bib28) 2005; 2 Cox, Patriarca, Treanor (bib37) 2008; 2 Holtz, Anderson, Cox (bib9) 2003; 2 Zhang, Klutch, Muller, Marcus-Sekura (bib18) 1994; 22 Treanor, Schiff, Hayden, Brady, Hay, Meyer (bib3) 2007; 297 Carreno, Esparza (bib23) 1977; 8 Hehme N, Engelmann H, Raderecht C, Porstmann T. Comparative laboratory results of different commercial influenza vaccines. Option for the control of influenza V, Okinawa, Japan; 2003. Poster W07P-41. Patch, Chattopadhyay, Hauser, Levine (bib24) 1981; 41 Safdar, Rodriguez, Fayad, Rodriguez, Pro, Wang (bib38) 2006; 194 Khan, Muller, Sears (bib26) 2001; 79 Baines, McGovern, Persing, Gostout (bib30) 2005; 123 Khan (10.1016/j.biologicals.2009.02.014_bib26) 2001; 79 Terzian (10.1016/j.biologicals.2009.02.014_bib32) 2001; 1 Kuno (10.1016/j.biologicals.2009.02.014_bib17) 2005; 18 Carreno (10.1016/j.biologicals.2009.02.014_bib23) 1977; 8 McPherson (10.1016/j.biologicals.2009.02.014_bib21) 2008 Khan (10.1016/j.biologicals.2009.02.014_bib25) 2001; 106 Li (10.1016/j.biologicals.2009.02.014_bib33) 2007; 81 Renfrey (10.1016/j.biologicals.2009.02.014_bib39) 1994; 12 Huhtala (10.1016/j.biologicals.2009.02.014_bib27) 2005; 118 Patch (10.1016/j.biologicals.2009.02.014_bib24) 1981; 41 Treanor (10.1016/j.biologicals.2009.02.014_bib2) 2006; 193 Kida (10.1016/j.biologicals.2009.02.014_bib11) 1983; 76 Knezevic (10.1016/j.biologicals.2009.02.014_bib19) 2008; 36 Wang (10.1016/j.biologicals.2009.02.014_bib10) 2006; 24 Cox (10.1016/j.biologicals.2009.02.014_bib1) 2007; 1 Rohwer (10.1016/j.biologicals.2009.02.014_bib13) 1996; 88 Baines (10.1016/j.biologicals.2009.02.014_bib30) 2005; 123 Keitel (10.1016/j.biologicals.2009.02.014_bib4) 1996; 3 Jarrett (10.1016/j.biologicals.2009.02.014_bib29) 2006; 123 (10.1016/j.biologicals.2009.02.014_bib35) 2007 Safdar (10.1016/j.biologicals.2009.02.014_bib38) 2006; 194 Bridges (10.1016/j.biologicals.2009.02.014_bib7) 2002; 51 Huber (10.1016/j.biologicals.2009.02.014_bib8) 2008; 10 Rose (10.1016/j.biologicals.2009.02.014_bib31) 1998; 26 Vaughn (10.1016/j.biologicals.2009.02.014_bib20) 1977; 13 Wood (10.1016/j.biologicals.2009.02.014_bib6) 1998 Zhang (10.1016/j.biologicals.2009.02.014_bib18) 1994; 22 Rose (10.1016/j.biologicals.2009.02.014_bib28) 2005; 2 Green (10.1016/j.biologicals.2009.02.014_bib22) 1975; 190 (10.1016/j.biologicals.2009.02.014_bib34) 2007 Cox (10.1016/j.biologicals.2009.02.014_bib37) 2008; 2 10.1016/j.biologicals.2009.02.014_bib40 Chen (10.1016/j.biologicals.2009.02.014_bib15) 2008 Treanor (10.1016/j.biologicals.2009.02.014_bib3) 2007; 297 Keitel (10.1016/j.biologicals.2009.02.014_bib5) 1994; 32 (10.1016/j.biologicals.2009.02.014_bib16) 1998 Holtz (10.1016/j.biologicals.2009.02.014_bib9) 2003; 2 Nims (10.1016/j.biologicals.2009.02.014_bib14) 2006; 123 (10.1016/j.biologicals.2009.02.014_bib36) 2007 Yoden (10.1016/j.biologicals.2009.02.014_bib12) 1986; 4 |
| References_xml | – volume: 190 start-page: 1099 year: 1975 end-page: 1101 ident: bib22 article-title: 5-Iododeoxyuridine potentiation of the replication in vitro of several unrelated RNA and DNA viruses publication-title: Science – volume: 3 start-page: 507 year: 1996 end-page: 510 ident: bib4 article-title: Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly publication-title: Clin Diagn Lab Immunol – year: 2007 ident: bib36 article-title: NCT00539864: Safety and reactogenicity of FluBlok and comparison of immunogenicity, efficacy and effectiveness against TIV – volume: 193 start-page: 1223 year: 2006 end-page: 1228 ident: bib2 article-title: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults publication-title: J Infect Dis – volume: 51 start-page: 1 year: 2002 end-page: 31 ident: bib7 article-title: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep – volume: 88 start-page: 247 year: 1996 end-page: 256 ident: bib13 article-title: Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE) publication-title: Dev Biol Stand – reference: Hehme N, Engelmann H, Raderecht C, Porstmann T. Comparative laboratory results of different commercial influenza vaccines. Option for the control of influenza V, Okinawa, Japan; 2003. Poster W07P-41. – volume: 13 start-page: 213 year: 1977 end-page: 217 ident: bib20 article-title: The establishment of two cell lines from the insect publication-title: In Vitro – year: 2007 ident: bib34 article-title: NCT00395174: Comparison of the immunogenicity, safety and reactogenicity of FluBlØk™, to a licensed vaccine in elderly adults – volume: 36 start-page: 203 year: 2008 end-page: 211 ident: bib19 article-title: WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11–12 June 2007 publication-title: Biologicals – volume: 1 start-page: 35 year: 2007 end-page: 40 ident: bib1 article-title: Production of a novel influenza vaccine using insect cells: protection against drifted strains publication-title: Influenza Other Respir Viruses – volume: 297 start-page: 1577 year: 2007 end-page: 1582 ident: bib3 article-title: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial publication-title: JAMA – volume: 4 start-page: 251 year: 1986 end-page: 261 ident: bib12 article-title: Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody publication-title: Virus Res – volume: 123 start-page: 153 year: 2006 end-page: 164 ident: bib14 article-title: Detection of adventitious viruses in biologicals – a rare occurrence publication-title: Dev Biol (Basel) – volume: 12 start-page: 747 year: 1994 end-page: 752 ident: bib39 article-title: Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom publication-title: Vaccine – volume: 18 start-page: 608 year: 2005 end-page: 637 ident: bib17 article-title: Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends publication-title: Clin Microbiol Rev – volume: 2 start-page: 20 year: 2005 ident: bib28 article-title: CODEHOP-mediated PCR – a powerful technique for the identification and characterization of viral genomes publication-title: Virol J – volume: 106 start-page: 387 year: 2001 end-page: 392 ident: bib25 article-title: Pert analysis of endogenous retroviruses induced from K-BALB mouse cells treated with 5-iododeoxyuridine: a potential strategy for detection of inducible retroviruses from vaccine cell substrates publication-title: Dev Biol (Basel) – year: 1998 ident: bib6 article-title: Standardization of inactivated influenza vaccine – year: 2007 ident: bib35 article-title: NCT00539981: Immunogenicity, safety, reactogenicity, efficacy, effectiveness and lot consistency of FluBlok – volume: 8 start-page: 193 year: 1977 end-page: 203 ident: bib23 article-title: Induction of Venezuelan equine encephalitis (Mucambo) virus by iododeoxyuridine in chronically infected ‘cured’ cultured mosquito cells publication-title: Intervirology – volume: 118 start-page: 278 year: 2005 end-page: 289 ident: bib27 article-title: Protein response of insect cells to bioreactor environmental stresses publication-title: J Biotechnol – volume: 79 start-page: 39 year: 2001 end-page: 45 ident: bib26 article-title: Early detection of endogenous retroviruses in chemically induced mouse cells publication-title: Virus Res – volume: 76 start-page: 91 year: 1983 end-page: 99 ident: bib11 article-title: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus publication-title: Arch Virol – year: 2008 ident: bib15 article-title: Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization – a case study publication-title: Biologicals – volume: 2 start-page: 201 year: 2008 end-page: 209 ident: bib37 article-title: FluBlok, a recombinant hemagglutinin influenza vaccine publication-title: Influenza Other Respir Viruses – volume: 123 start-page: 81 year: 2005 end-page: 87 ident: bib30 article-title: Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomas publication-title: J Virol Methods – volume: 2 start-page: 25 year: 2003 end-page: 32 ident: bib9 article-title: Production of a recombinant influenza vaccine using the baculovirus expression vector system publication-title: Bioprocess J – volume: 194 start-page: 1394 year: 2006 end-page: 1397 ident: bib38 article-title: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma publication-title: J Infect Dis – volume: 26 start-page: 1628 year: 1998 end-page: 1635 ident: bib31 article-title: Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences publication-title: Nucleic Acids Res – volume: 22 start-page: 205 year: 1994 end-page: 213 ident: bib18 article-title: Susceptibility of the Sf9 insect cell line to infection with adventitious viruses publication-title: Biologicals – volume: 10 start-page: 75 year: 2008 end-page: 85 ident: bib8 article-title: FluBlok, a recombinant influenza vaccine publication-title: Curr Opin Mol Ther – volume: 24 start-page: 2176 year: 2006 end-page: 2185 ident: bib10 article-title: Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine publication-title: Vaccine – volume: 1 start-page: 3 year: 2001 ident: bib32 article-title: Evolution and phylogeny of insect endogenous retroviruses publication-title: BMC Evol Biol – volume: 123 start-page: 77 year: 2006 end-page: 88 ident: bib29 article-title: Molecular methods for virus discovery publication-title: Dev Biol (Basel) – volume: 41 start-page: 2421 year: 1981 end-page: 2427 ident: bib24 article-title: Regulation of viral transcription in cells infected with iododeoxyuridine-substituted simian virus 40 as a model for the activation by iododeoxyuridine of latent viral genomes publication-title: Cancer Res – year: 2008 ident: bib21 article-title: Development of a novel recombinant influenza vaccine in insect cells publication-title: Biologicals – year: 1998 ident: bib16 publication-title: The insect viruses – volume: 32 start-page: 2468 year: 1994 end-page: 2473 ident: bib5 article-title: High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults publication-title: J Clin Microbiol – volume: 81 start-page: 10890 year: 2007 end-page: 10896 ident: bib33 article-title: Latent infection of a new alphanodavirus in an insect cell line publication-title: J Virol – volume: 2 start-page: 20 year: 2005 ident: 10.1016/j.biologicals.2009.02.014_bib28 article-title: CODEHOP-mediated PCR – a powerful technique for the identification and characterization of viral genomes publication-title: Virol J doi: 10.1186/1743-422X-2-20 – volume: 190 start-page: 1099 issue: 4219 year: 1975 ident: 10.1016/j.biologicals.2009.02.014_bib22 article-title: 5-Iododeoxyuridine potentiation of the replication in vitro of several unrelated RNA and DNA viruses publication-title: Science doi: 10.1126/science.1188388 – volume: 8 start-page: 193 issue: 4 year: 1977 ident: 10.1016/j.biologicals.2009.02.014_bib23 article-title: Induction of Venezuelan equine encephalitis (Mucambo) virus by iododeoxyuridine in chronically infected ‘cured’ cultured mosquito cells publication-title: Intervirology doi: 10.1159/000148895 – volume: 1 start-page: 35 issue: 1 year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib1 article-title: Production of a novel influenza vaccine using insect cells: protection against drifted strains publication-title: Influenza Other Respir Viruses doi: 10.1111/j.1750-2659.2006.00007.x – volume: 12 start-page: 747 issue: 8 year: 1994 ident: 10.1016/j.biologicals.2009.02.014_bib39 article-title: Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom publication-title: Vaccine doi: 10.1016/0264-410X(94)90227-5 – volume: 123 start-page: 153 year: 2006 ident: 10.1016/j.biologicals.2009.02.014_bib14 article-title: Detection of adventitious viruses in biologicals – a rare occurrence publication-title: Dev Biol (Basel) – volume: 123 start-page: 77 year: 2006 ident: 10.1016/j.biologicals.2009.02.014_bib29 article-title: Molecular methods for virus discovery publication-title: Dev Biol (Basel) – volume: 2 start-page: 25 year: 2003 ident: 10.1016/j.biologicals.2009.02.014_bib9 article-title: Production of a recombinant influenza vaccine using the baculovirus expression vector system publication-title: Bioprocess J doi: 10.12665/J25.Holtz – year: 2008 ident: 10.1016/j.biologicals.2009.02.014_bib15 article-title: Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization – a case study publication-title: Biologicals doi: 10.1016/j.biologicals.2008.07.005 – volume: 36 start-page: 203 issue: 3 year: 2008 ident: 10.1016/j.biologicals.2009.02.014_bib19 article-title: WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11–12 June 2007 publication-title: Biologicals doi: 10.1016/j.biologicals.2007.11.005 – volume: 88 start-page: 247 year: 1996 ident: 10.1016/j.biologicals.2009.02.014_bib13 article-title: Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE) publication-title: Dev Biol Stand – volume: 194 start-page: 1394 issue: 10 year: 2006 ident: 10.1016/j.biologicals.2009.02.014_bib38 article-title: Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma publication-title: J Infect Dis doi: 10.1086/508493 – volume: 297 start-page: 1577 issue: 14 year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib3 article-title: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.297.14.1577 – year: 1998 ident: 10.1016/j.biologicals.2009.02.014_bib16 – volume: 106 start-page: 387 year: 2001 ident: 10.1016/j.biologicals.2009.02.014_bib25 article-title: Pert analysis of endogenous retroviruses induced from K-BALB mouse cells treated with 5-iododeoxyuridine: a potential strategy for detection of inducible retroviruses from vaccine cell substrates publication-title: Dev Biol (Basel) – year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib35 – volume: 81 start-page: 10890 issue: 20 year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib33 article-title: Latent infection of a new alphanodavirus in an insect cell line publication-title: J Virol doi: 10.1128/JVI.00807-07 – volume: 18 start-page: 608 issue: 4 year: 2005 ident: 10.1016/j.biologicals.2009.02.014_bib17 article-title: Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends publication-title: Clin Microbiol Rev doi: 10.1128/CMR.18.4.608-637.2005 – year: 2008 ident: 10.1016/j.biologicals.2009.02.014_bib21 article-title: Development of a novel recombinant influenza vaccine in insect cells publication-title: Biologicals doi: 10.1016/j.biologicals.2008.08.001 – volume: 118 start-page: 278 issue: 3 year: 2005 ident: 10.1016/j.biologicals.2009.02.014_bib27 article-title: Protein response of insect cells to bioreactor environmental stresses publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2005.05.009 – volume: 1 start-page: 3 year: 2001 ident: 10.1016/j.biologicals.2009.02.014_bib32 article-title: Evolution and phylogeny of insect endogenous retroviruses publication-title: BMC Evol Biol doi: 10.1186/1471-2148-1-3 – volume: 79 start-page: 39 issue: 1–2 year: 2001 ident: 10.1016/j.biologicals.2009.02.014_bib26 article-title: Early detection of endogenous retroviruses in chemically induced mouse cells publication-title: Virus Res doi: 10.1016/S0168-1702(01)00280-5 – volume: 10 start-page: 75 issue: 1 year: 2008 ident: 10.1016/j.biologicals.2009.02.014_bib8 article-title: FluBlok, a recombinant influenza vaccine publication-title: Curr Opin Mol Ther – volume: 22 start-page: 205 issue: 3 year: 1994 ident: 10.1016/j.biologicals.2009.02.014_bib18 article-title: Susceptibility of the Sf9 insect cell line to infection with adventitious viruses publication-title: Biologicals doi: 10.1006/biol.1994.1030 – year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib34 – volume: 26 start-page: 1628 issue: 7 year: 1998 ident: 10.1016/j.biologicals.2009.02.014_bib31 article-title: Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences publication-title: Nucleic Acids Res doi: 10.1093/nar/26.7.1628 – volume: 4 start-page: 251 issue: 3 year: 1986 ident: 10.1016/j.biologicals.2009.02.014_bib12 article-title: Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody publication-title: Virus Res doi: 10.1016/0168-1702(86)90004-3 – year: 1998 ident: 10.1016/j.biologicals.2009.02.014_bib6 – volume: 2 start-page: 201 issue: 6 year: 2008 ident: 10.1016/j.biologicals.2009.02.014_bib37 article-title: FluBlok, a recombinant hemagglutinin influenza vaccine publication-title: Influenza Other Respir Viruses doi: 10.1111/j.1750-2659.2008.00053.x – volume: 13 start-page: 213 issue: 4 year: 1977 ident: 10.1016/j.biologicals.2009.02.014_bib20 article-title: The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae) publication-title: In Vitro doi: 10.1007/BF02615077 – volume: 3 start-page: 507 issue: 5 year: 1996 ident: 10.1016/j.biologicals.2009.02.014_bib4 article-title: Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.3.5.507-510.1996 – volume: 41 start-page: 2421 issue: 6 year: 1981 ident: 10.1016/j.biologicals.2009.02.014_bib24 article-title: Regulation of viral transcription in cells infected with iododeoxyuridine-substituted simian virus 40 as a model for the activation by iododeoxyuridine of latent viral genomes publication-title: Cancer Res – volume: 123 start-page: 81 issue: 1 year: 2005 ident: 10.1016/j.biologicals.2009.02.014_bib30 article-title: Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomas publication-title: J Virol Methods doi: 10.1016/j.jviromet.2004.08.020 – volume: 32 start-page: 2468 issue: 10 year: 1994 ident: 10.1016/j.biologicals.2009.02.014_bib5 article-title: High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults publication-title: J Clin Microbiol doi: 10.1128/JCM.32.10.2468-2473.1994 – volume: 24 start-page: 2176 issue: 12 year: 2006 ident: 10.1016/j.biologicals.2009.02.014_bib10 article-title: Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2005.11.005 – volume: 76 start-page: 91 issue: 2 year: 1983 ident: 10.1016/j.biologicals.2009.02.014_bib11 article-title: Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus publication-title: Arch Virol doi: 10.1007/BF01311693 – volume: 193 start-page: 1223 issue: 9 year: 2006 ident: 10.1016/j.biologicals.2009.02.014_bib2 article-title: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults publication-title: J Infect Dis doi: 10.1086/503050 – year: 2007 ident: 10.1016/j.biologicals.2009.02.014_bib36 – ident: 10.1016/j.biologicals.2009.02.014_bib40 – volume: 51 start-page: 1 issue: RR-3 year: 2002 ident: 10.1016/j.biologicals.2009.02.014_bib7 article-title: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep |
| SSID | ssj0011474 |
| Score | 2.264188 |
| SecondaryResourceType | review_article |
| Snippet | FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 182 |
| SubjectTerms | Animals Baculovirus Cell substrate Hemagglutinin Influenza vaccine Influenza Vaccines - genetics Insect cells Insecta - genetics Vaccines, Synthetic - genetics |
| Title | FluBlok, a next generation influenza vaccine manufactured in insect cells |
| URI | https://dx.doi.org/10.1016/j.biologicals.2009.02.014 https://www.ncbi.nlm.nih.gov/pubmed/19297194 https://www.proquest.com/docview/20628052 https://www.proquest.com/docview/67276229 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB-s0tKXYu2HV_W6Qh8bL9nsbrLgix49zipS2gq-hf2Uq9eceBfBPvRvdzYfah8OhJI8JTuw_GYyM9nZ_Q3Ap0Q5YaS1EZM2ixjNdCS94hHnqTBce_SbNdvnqRifsa_n_HwFht1ZmLCtsvX9jU-vvXX7ZNCiObiaTAY_kkCNgvE7lvUaEf4CrdFUCjTttYOj4_HpfTEhYTUZcxgfBYEXsPuwzavhOgqAzFv2SroXJ2xZmFqWhtbhaLQOr9o8khw0U30NK67cgOdNZ8nbN3A0mlaH09nlZ6JIif6XXNT00kELZNL0JfmjyI0yoa5OfquyCiccqmtn8TXec8SEhEX9-Vs4G335ORxHbdeEyLCMLiKTZDkzVuSCo5XolFspcsUwkOeehwOTTktlpXE-xUtxaWjmE57n3tc11_QdrJaz0m0CiXNlndaCOhozxlOtraDeG_znU-gIfA_yDqTCtJTiobPFtOj2jv0qHuEbWl7KIqYF4tsDei961fBqPEVov9NE8Y-RFOj_nyL-sdNegR9RAFGVblaFQQhMzOnyEaFgLSiVPXjfqP1h1phgZolkH_5vclvwsilUhQWebVhdXFduB_Odhe7Ds72_SR-tevj95Fu_te47h4QCow |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5VRTwuiHeXV43EkXQTr-3EEheoWG2h9EIr9Wb5iRa22aq7QYIDv52ZPFo4rFQJJadkLFnf2DNjj_0NwOvCRuV1CJnQocwEL12mk5WZlBPlpUtoN1u2zyM1OxEfT-XpFuwPd2HoWGVv-zub3lrr_su4R3N8Pp-PvxREjYL-O9ftHhEugW4InL40O_d-X57zwHi_pWIm6YzEb8Grq0NeHdMRwbHquSv5Xl6ITU5qUxDaOqPpPbjbR5HsXdfR-7AV6wdws6sr-fMhHEwXzfvF8vsbZlmN1pd9bcmlSQds3lUl-WXZD-spq87ObN3Q_YbmIgb8je8KEWG0pb96BCfTD8f7s6yvmZB5UfJ15ouyEj6oSkkcI24ig1aVFejGqyTpumR02gbtY5rgY6X2vEyFrKqU2ozr5DFs18s67gDLKxuic4pHngtE1rmgeEoeV3wWzUAaQTWAZHxPKE51LRZmODn2zfyFLxW81CbnBvEdAb9set6xalyn0dtBE-afIWLQ-l-n-e6gPYNTiEC0dVw2JITA5JJvlqB0teJcj-BJp_arXmN4WRZaPP2_zu3C7dnx50NzeHD06Rnc6VJWtNXzHLbXF018gZHP2r1sR_Yfll4B0g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FluBlok%2C+a+next+generation+influenza+vaccine+manufactured+in+insect+cells&rft.jtitle=Biologicals&rft.au=Cox%2C+Manon+M+J&rft.au=Hollister%2C+Jason+R&rft.date=2009-06-01&rft.eissn=1095-8320&rft.volume=37&rft.issue=3&rft.spage=182&rft_id=info:doi/10.1016%2Fj.biologicals.2009.02.014&rft_id=info%3Apmid%2F19297194&rft.externalDocID=19297194 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-1056&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-1056&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-1056&client=summon |